

DUX4 pathological expression: causes and consequences in cancer

Carla Dib^{1,2}, Vlada Zakharova^{1,2,4}, Ekaterina Popova³, Ekaterina Kiseleva⁵, Boris Chernyak³, Marc Lipinski^{1,2}, Yegor S. Vassetzky^{1,2,5,6}

¹UMR 8126, CNRS, Univ. Paris-Sud, Université Paris Saclay, Institut Gustave Roussy, F-94805 Villejuif, France

²LIA 1066 LFR2O French-Russian Joint Cancer Research Laboratory, 94805 Villejuif, France

³Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow, Russia

⁴CNRS UMR7216 "Epigénétique et Destin Cellulaire" Université Paris Diderot Paris 7

⁵Koltzov Institute of Developmental Biology, Moscow 117334, Russia

⁶To whom correspondence should be addressed:

Yegor S. Vassetzky,
CNRS UMR8126,
Institut Gustave Roussy,
F-94805 Villejuif, France
Tel: +(33)142116283 ;
E-mail: vassetzky@igr.fr

Keywords: DUX4, Leukaemia, Sarcoma, FSHD

Word count: 1160

Abstract

DUX4, a double homeobox transcription factor, has been mostly studied in facioscapulohumeral dystrophy (FSHD), a pathology linked to a deletion of subtelomeric repeats on chromosome 4q. More recently, however, the gene has been associated with various sarcomas and hematological malignancies. Drugs developed for FSHD could be tested on cancer cells to develop efficient treatment strategies for both pathologies.

DUX4 is a double homeobox transcription factor encoded within the D4Z4 subtelomeric repeat element on chromosome 4q. Recently, *DUX4* rearrangements were reported in a frequent paediatric subtype of B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) (reviewed in [1]), in Ewing-like sarcoma [2] and rhabdomyosarcoma (RMS) [3]. Previously, aberrant expression of *DUX4* was identified as a major factor in the aetiology of facioscapulohumeral dystrophy (FSHD), an autosomal dominant disorder. Below, we discuss features and consequences of *DUX4* gene rearrangements in malignancies and new therapeutic approaches in the context of FSHD that might prove useful for cancer treatment.

***DUX4* expression and gene rearrangements**

In humans, an aberrantly expressed *DUX4* has been observed in numerous malignancies including renal, breast and testicular cancers (source: Human Protein Atlas¹). Translocations (4;19) have been observed in Ewing-like sarcomas resulting in portions of *DUX4* fused with partner genes. One translocation produced a fused protein associating the N-terminal part of CIC, an ETS family transcription factor, and the C-terminus of *DUX4* (Figure 1A) resulting in a dysregulation of the transcriptional activity of the fused gene [2]. In embryonic rhabdomyosarcoma (RMS), a t(4;22) rearrangement led to the production of an EWSR1-*DUX4* chimeric protein [3]. Other *DUX4* rearrangements included the insertion of a truncated copy of *DUX4* into either an intron of *ERG* [4] or the *IGH* gene locus [1] (Figure 1B,C), characteristic of a subtype of BCP-ALL. Both chimeric proteins had a *DUX4* C-terminal truncation. Additionally, some *DUX4* C-terminal aminoacids have been found replaced by aminoacids encoded by non-coding parts of the partner gene.

***DUX4* regulation in normal and pathological conditions**

Most data concerning the function and regulation of *DUX4* were generated from studies in FSHD [5]. The subtelomeric D4Z4 repeat has long been considered as "junk" DNA until *DUX4* transcripts were discovered in FSHD muscle cells following the identification of an open reading frame (ORF) encoding two homeoboxes [6]. *DUX4* expression is controlled by two *DUX4*-specific enhancers and an insulator proximal to the D4Z4 repeat [7]. Epigenetic modifications including DNA hypomethylation of D4Z4 units reported in FSHD patients appear to correlate with the severity of the disease [8]. Non-coding RNAs, miRNAs, telomere shortening, and long-range chromatin interactions also affect the expression of *DUX4*. In BCP-ALL, following the translocation, *DUX4* transcription is regulated by control elements in the partner region which further provides the poly-A signal. An additional *DUX4* activation may result from relocation from a repressed to an actively

transcribed nuclear compartment. Similar to the CIC-DUX4 chimeric transcript regulated by the CIC promoter in the t(4;19) translocation found in a Ewing-like sarcoma, the expression of the EWSR1-DUX4 fused gene in the RMS with a t(4;22) translocation probably results from the activity of the EWSR1 promoter [3]. In other cancers, additional abnormalities of *DUX4* have been observed including epigenetic alterations within the 4q35 FSHD-associated locus. Triggered by those observations, expression profiles compared FSHD and 35 different cancers revealing a significant level of similarity between FSHD and Ewing-like sarcomas [9].

***DUX4* domains and functional predictions**

The N-terminal part of the 424 aminoacid-long *DUX4* protein harbors two homeodomains and three nuclear localization sequences (NLS). The C-terminal domain contains a domain of interaction with the histone acetyltransferase p300/CBP and two distinct transcription regulation signals required for *DUX4*-induced cytotoxicity. Thus, the CIC- and EWSR1-*DUX4* fusion proteins should combine the DNA-binding specificity of CIC/EWSR1 with the transcriptional regulation and p300/CBP-binding capacities of *DUX4*. Based on experimental observations, truncation or replacement of the C-terminus should reduce/modify the transcriptional activation capacity of *DUX4* [10] and inhibit interaction with p300/CBP. Indeed, the C-terminus truncated, but not the full-length copy, of *DUX4* induced leukemic transformation rather than apoptosis [4].

Pathological consequences of *DUX4* expression

In FSHD myotubes, an overexpression of *DUX4* induces cellular atrophy *via* activation of MuRF1 and MAFbx/atrogen-1, two E3 ubiquitin ligases and apoptosis *via* caspase 3 and p53. *DUX4* deregulates myogenic differentiation by decreasing *MYOD* expression and induces aberrant expression of genes normally expressed specifically in germ cells. *DUX4* expression additionally leads to production of reactive oxygen species (ROS) and DNA damage [11,12]. In cancer, *DUX4*-induced ROS may induce mutations and chromosomal aberrations that contribute to malignant transformation (Figure 1D). Significantly, FSHD cells show transcriptional profiles similar to some cancer cells [9]. In leukaemia cells, *DUX4* induces expression of ERG dominant negative isoforms resulting in the loss of function of wild-type ERG which is essential for leukemogenesis [13]. In nude mice expressing *IGH-DUX4* but not *DUX4* in pro-B cells generated a B-cell leukaemia suggesting that *DUX4* gains an oncogenic potential following chromosomal rearrangement [1]. In the BCP-ALL subtype, *DUX4*-induced DNA damage can account for the frequent deletion of ERG and additional chromosomal aberrations which constitute a hallmark in this disease. In Ewing-like sarcoma, the CIC-*DUX4* fusion results in changes in CIC transcriptional activity leading to

upregulation of the PEA3 transcription factor that regulates many genes involved in oncogenesis [2].

***DUX4*: therapeutic opportunities**

Several genetic and epigenetic approaches have been developed to inhibit *DUX4* expression in the context of FSHD, including small interfering RNAs, antisense oligonucleotides, Morpholinos impeding polyadenylation or intron splicing, as well as microRNAs directly targeting *DUX4*. The promoter and exon 1 of *DUX4* have been targeted by a dCas9-KRAB fusion protein, with KRAB significantly decreasing the expression levels of *DUX4* and downstream genes [14]. Recently, compounds with epigenetic activity including some under test in clinical trials were used in screens to identify molecules that decrease or suppress *DUX4* expression in FSHD myoblasts. Among different classes of molecules, inhibitors of the BET (bromodomain and extra-terminal) domain and beta-2 adrenergic receptor agonists have been identified [15]. Since aberrant expression of *DUX4* fusion proteins induces leukemic transformation [4], some of these approaches could be potentially useful in cancers where *DUX4* is rearranged and overexpressed.

Concluding Remarks and Future Perspectives

Numerous similarities exist in the transcriptional signatures of FSHD myoblasts and several cancers [9]. Recent discovery of the role of *DUX4* in cancer provide new opportunities for both FSHD and cancer research and treatment. Cancer cells from patients with high expression of *DUX4* fusion genes may provide human experimental models for *DUX4*-targeted drug screening. *Vice versa*, therapies developed for FSHD may prove of interest in cancer treatment. Future perspectives include the use of *DUX4*-targeting drugs developed for FSHD to silence its expression in cancer cells and possibly inhibit cancer cell growth. As *DUX4* is not expressed in somatic tissues, it can be considered a “safe” target for cancer therapy.

Acknowledgements

The work was supported by grants from AFM (MEGAFSHD) to YV, from the Presidium of RAS and the State program of fundamental scientific research of IDB RAS to EK and YV, and from the Russian Foundation for Basic Research (No 19-04-01020) to EP.

Disclaimer Statement

The authors declare no conflict of interest.

Figure Legend

Figure 1. *DUX4* rearrangements in cancer (A-C) and physiological consequences of its aberrant expression (D). (A), in Ewing-like sarcoma, the t(4;19)(q35;q13) chromosomal translocation generates a fusion between the *DUX4* C-terminus and the *CIC* gene. This fusion results in the production of CIC-DUX4 chimeric protein under the control of the *CIC* promoter; in ALL, translocation of a truncated or complete copy of *DUX4* into an intron of *ERG* t(4;21)(q35;q22) (B) or into the *IGH* locus t(4;14)(q35;q32) (C) leads to expression of truncated or chimeric proteins. (D), pathological consequences of aberrant expression of *DUX4* include transcription factors deregulation, apoptosis, leukemogenesis, oxidative stress, DNA damage and deregulation of myogenesis.

Resources


ⁱ<https://www.proteinatlas.org/ENSG00000260596-DUX4/pathology>

References

- 1 Lilljebjörn, H. and Fioretos, T. (2017) New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia. *Blood* 130, 1395–1401
- 2 Kawamura-Saito, M. *et al.* (2006) Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. *Hum. Mol. Genet.* 15, 2125–37
- 3 Sirvent, N. *et al.* (2009) Fusion of EWSR1 with the DUX4 facioscapulohumeral muscular dystrophy region resulting from t(4;22)(q35;q12) in a case of embryonal rhabdomyosarcoma. *Cancer Genet. Cytogenet.* 195, 12–18
- 4 Yasuda, T. *et al.* (2016) Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. *Nat. Genet.* 48, 569–574
- 5 Lemmers, R.J.L.F. *et al.* (2010) A unifying genetic model for facioscapulohumeral muscular dystrophy. *Science* (80-.). 329, 1650–1653
- 6 Dixit, M. *et al.* (2007) DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. *Proc Natl Acad Sci U S A* 104, 18157–18162
- 7 Petrov, A. *et al.* (2008) A nuclear matrix attachment site in the 4q35 locus has an enhancer-blocking activity in vivo: implications for the facio-scapulo-humeral dystrophy. *Genome Res.* 18, 39–45
- 8 van Overveld, P.G. *et al.* (2003) Hypomethylation of D4Z4 in 4q-linked and non-4q-

- linked facioscapulohumeral muscular dystrophy. *Nat Genet* 35, 315–317
- 9 Dmitriev, P. *et al.* (2014) Cancer-related genes in the transcription signature of facioscapulohumeral dystrophy myoblasts and myotubes. *J Cell Mol Med* 18, 208–217
- 10 Tanaka, Y. *et al.* (2018) Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia. *Haematologica* 103, e522–e526
- 11 Dmitriev, P. *et al.* (2016) DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients. *Free Radic. Biol. Med.* 99, 244–258
- 12 Bosnakovski, D. *et al.* (2008) An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. *EMBO J* 27, 2766–2779
- 13 Dong, X. *et al.* (2018) Structural basis of DUX4/IGH-driven transactivation. *Leukemia* 32, 1466–1476
- 14 Himeda, C.L. *et al.* (2018) Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy. *Mol. Ther.* 26, 1797–1807
- 15 Campbell, A.E. *et al.* (2017) BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells. *Skelet. Muscle* 7, 16


A




ERG-DUX4
(Acute
Lymphoblastic
Leukemia)

CIC-DUX4
fusion
(Ewing-like
Sarcoma)

B



C



IGH-DUX4
(Acute
Lymphoblastic
Leukemia)

D

